Akoya Biosciences Inc expected to post a loss of 20 cents a share - Earnings Preview

Akoya Biosciences

12/11/2024 23:36

* Akoya Biosciences Inc  AKYA.OQ   AKYA.O  is expected
to show a
rise in quarterly revenue when it reports  results on November
14 for the period ending September 30 2024
    * The Marlborough Massachusetts-based  company is expected
to
report a 1.2% increase in revenue to $25.421 million from $25.13
million a year ago, according to the mean estimate from 7
analysts, based on LSEG data.
    * ​LSEG's mean analyst estimate for Akoya Biosciences Inc is
for a
loss of 20 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 4 "strong buy" or "buy," 4
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Akoya
Biosciences
Inc is $4.00​, above​ its last closing price of $3.19. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Jun. 30 2024  -0.27       -0.27      -0.27     Met     -0.8
 Mar. 31 2024  -0.29       -0.29      -0.48     Missed  -66.2
 Dec. 31 2023  -0.27       -0.27      -0.22     Beat    18.1​
 Sep. 30 2023  -0.36       -0.37      -0.26     Beat    28.9
 ​​Jan.        -0.43       -0.44      -0.46     Missed  -3.9
 1 0001                                                 
 Mar. 31 2023  -0.50       -0.48      -0.49     Missed  -1.5​
 Jan. 1 0001   -0.44       -0.43      -0.50     Missed  -16.3
 Sep. 30 2022  -0.49       -0.44      -0.47     Missed  -6.8
 This summary was machine generated November 12 at 23:35 GMT. 
All figures in US dollars unless otherwise stated. (For
questions concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)